GH Research PLC
GHRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001855129
No open-market purchases or sales by GH Research PLC insiders were filed in the last 90 days; 63 institutions reported holding it in 13F filings for Q2 2026, worth $1.38B in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding GH Research PLC changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 29 | 35 | +6 |
| Shares | 29.0M | 29.6M | +597.0K (+2.1%) |
| Value | $291.5M | $171.7M | −$119.8M (−41.1%) |
New holders (6)
Institutions that held GH Research PLC at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Checkpoint Capital L.P. | 293,945 | $1.70M | 1.19% |
| Squarepoint Ops LLC | 41,279 | $239.4K | 0.00% |
| Two Sigma Investments, LP | 14,481 | $84.0K | 0.00% |
| Northern Trust Corp | 10,138 | $58.8K | 0.00% |
| JPMorgan Chase & Co | 600 | $3.48K | 0.00% |
| Simplex Trading, LLC | 99 | $0 | 0.00% |
Sold out (0)
Institutions that held GH Research PLC at the end of Q3 2023 and filed for Q4 2023 without it.
None.